Development of prediction model for fructose- 1,6- bisphosphatase inhibitors using the Monte Carlo method

References

• Q. Dang, S.R. Kasibhatla, K.R. Reddy, T. Jiang, M.R. Reddy, S.C. Potter, J.M. Fujitaki, P.D.V. Poelje, J. Huang, W.N. Lipscomb, and M.D. Erion, Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes, J. Am. Chem. Soc. 129 (2007), pp. 15491–15502.
   PubMed Web of Science ®Google Scholar
• S. Heng, K.R. Gryncel, and E.R. Kantrowitz, A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase, Bioorg. Med. Chem. 17 (2009), pp. 3916–3922.
   Web of Science ®Google Scholar
• J. Bie, S. Liu, J. Zhou, B. Xu, and Z. Shen, Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase, Bioorg. Med. Chem. 22 (2014), pp. 1850–1864.
   Google Scholar
• Q. Dang, B.S. Brown, Y. Liu, R.M. Rydzewski, E.D. Robinson, P.D.V. Poelje, M.R. Reddy, and M.D. Erion, Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics, J. Med. Chem. 52 (2009), pp. 2880–2898.
   Google Scholar
• J. Bie, S. Liu, Z. Li, Y. Mu, B. Xu, and Z. Shen, Discovery of novel indole derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase, Eur. J. Med. Chem. 90 (2015), pp. 394–405.
   Web of Science ®Google Scholar
• M. Hao, X. Zhang, H. Ren, Y. Li, S. Zhang, F. Luo, M. Ji, G. Li, and L. Yang, In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors, Int. J. Mol. Sci. 12 (2011), pp. 8161–8180.
   Google Scholar
• T.W.V. Geldern, C. Lai, R.J. Gum, M. Daly, C. Sun, E.H. Fryb, and C.A. Zapaterob, Benzoxazolebenzenesulfonamides are novel allosteric inhibitors of fructose-1,6-bisphosphatase with a distinct binding mode, Bioorg. Med. Chem. Lett. 16 (2006), pp. 1811–1815.
   PubMed Web of Science ®Google Scholar
• Q. Dang, S.R. Kasibthatla, T. Jiang, F. Taplin, T.Gibson, S.C. Potter, P.D.V. Poelje, and M.D. Erion, Oxazolephosphonic acids as fructose 1,6-bisphosphatase inhibitors with potent glucose-lowering activity, Med. Chem. Commun. 2 (2011), pp. 287–290.
   Google Scholar
• Q. Dang, S.R. Kasibhatla, W. Xiao, Y. Liu, J. DaRe, F. Taplin, K.R. Reddy, G.R. Scarlato, T. Gibson, P.D.V. Poelje, S.C. Potter, and M.D. Erion, Fructose-1,6-bisphosphatase inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 50-adenosinemonophosphate (AMP) mimics, J. Med. Chem. 53 (2010), pp. 441–451.
   PubMed Web of Science ®Google Scholar
• J.B. Veselinovic, A.M. Veselinovic, A.P. Toropova, and A.A. Toropov, The Monte Carlo technique as a tool to predict LOAEL, Eur. J. Med. Chem. 116 (2016), pp. 71–75.
   Web of Science ®Google Scholar
• A.A. Toropov and A.P. Toropova, CORAL, software available at http://www.insilico.eu/coral.
   Google Scholar
• K. Nesmerak, A.A. Toropov, A.P. Toropova, P. Kohoutova, and K. Waisser, SMILES-based quantitative structure property relationships for half-wave potential of N-benzylsalicylthioamides, Eur. J. Med. Chem. 67 (2013), pp. 111–114.
   Web of Science ®Google Scholar
• R. Gaikwad, S. Ghorai, Sk.A. Amin, N. Adhikari, T. Patel, K. Das, T. Jha, and S. Gayen, Monte Carlo based modelling approach for designing and predicting cytotoxicity of 2-phenylindole derivatives against breast cancer cell line MCF7, Toxicol. Vitro 52 (2018), pp. 23–32.
   Google Scholar
• P. Hebeisen, W. Haap, B. Kuhn, P. Mohr, H.P. Wessel, U. Zutter, S. Kirchner, A. Ruf, J. Benz, C. Joseph, R.A. Sánchez, M. Gubler, B. Schott, A. Benardeau E. Tozzo, and E. Kitas, Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase, Bioorg. Med. Chem. Lett. 21 (2011), pp. 3237–3242.
   Google Scholar
• E. Kitas, P. Mohr, B. Kuhn, P. Hebeisen, H.P. Wessel, W. Haap, A. Ruf, J. Benz, C. Joseph, W. Huber, R.A. Sanchez, A. Paehler, A. Benardeau, M. Gubler, B. Schott, and E. Tozzo, Sulfonylureidothiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of Type-2 diabetes, Bioorg. Med. Chem. Lett. 20 (2010), pp. 594–599.
   PubMed Web of Science ®Google Scholar
• A.M. Veselinović, A. Toropov, A. Toropova, D.S. Đorđević, and J.B. Veselinović, Design and development of novel antibiotics based on FtsZ inhibition - in silico studies, New J. Chem. 42 (2018), pp. 10976–10982.
   Web of Science ®Google Scholar
• V. Prachayasittikul, A. Worachartcheewan, A.P. Toropova, A.A. Toropov, N. Schaduangrat, V. Prachayasittikul, and C. Nantasenamat, Large-scale classification of P-glycoprotein inhibitors using SMILES-based descriptors, SAR QSAR Environ. Res. 28 (2017), pp. 1–16.
   Google Scholar
• J.B. Veselinović, G.M. Nikolić, N.V. Trutić, J.V. Živković, and A.M. Veselinović, Monte Carlo QSAR models for predicting organophosphate inhibition of acetycholinesterase, SAR QSAR Environ. Res. 26 (2015), pp. 449–460.
   Google Scholar
• P. Kumar and A. Kumar, Monte Carlo method based QSAR studies of Mer kinase inhibitors in compliance with OECD principles, Drug Res. 68 (2017), pp. 189–195.
   Google Scholar
• M. Gobbi, M.B. Mariya, A. Toropova, A.A. Toropov, and M. Salmona, Monte Carlo method for predicting of cardiac toxicity: hERG blocker compounds, Toxicol. Lett. 250–251 (2016), pp. 42–46.
   Google Scholar
• J.V. Živković, N.V. Trutić, J.B. Veselinović, G.M. Nikolić, and A.M. Veselinović, Monte Carlo method based QSAR modelling of male imide derivatives as glycogen synthase kinase-3β inhibitors, Comput. Biol. Med. 64 (2015), pp. 276–286.
   Google Scholar
• P.G.R. Acharya, Simplified molecular input line entry system-based optimal descriptors: QSAR modelling for voltage-gated potassium channel subunit Kv7.2, SAR QSAR Environ. Res. 25 (2014), pp. 73–90.
   Google Scholar
• A. Rescifina, G. Floresta, A. Marrazzo, C. Parenti, O. Prezzavento, G. Nastasi, M. Dichiara, and E. Amata, Development of a sigma-2 receptor affinity filter through a Monte Carlo based QSAR analysis, Eur. J. Pharma. Sci. 106 (2017), pp. 94–101.
   Web of Science ®Google Scholar
• D. Sokolović, D. Aleksić, V. Milenković, S. Karaleić, D. Mitić, J. Kocić, B. Mekić, J.B. Veselinović, and A.M. Veselinović, QSAR modeling of bis-quinolinium and bis-isoquinolinium compounds as acetylcholine esterase inhibitors based on the Monte Carlo method—the implication for myasthenia gravis treatment, Med. Chem. Res. 25 (2016), pp. 2989–2998.
   Google Scholar
• J.B. Veselinovic, A.A. Toropov, A.P. Toropova, G.M. Nikolic, and A.M. Veselinovic, Monte Carlo method-based QSAR modeling of penicillins binding to human serum proteins, Arch. Pharm. Chem. Life Sci. 348 (2015), pp. 62–67.
   Google Scholar
• P. Kumar, A. Kumar, J. Sindhu, and S. Lal, QSAR Models for nitrogen containing monophosphonate and bisphosphonate derivatives as human farnesyl pyrophosphate synthase inhibitors based on Monte Carlo method, Drug Res. (2018), doi: 10.1055/a-0652-5290 [ Epub ahead of print].
   Google Scholar
• K. Nesměrák, A.A. Toropov, A.P. Toropova, T.E. Bolelli, and I. Yildiz, QSAR of antimycobacterial activity of benzoxazoles by optimal SMILES-based descriptors, Med. Chem. Res. 26 (2017), pp. 3203–3208.
   Google Scholar
• S. Begum and P.G.R. Achary, Simplified molecular input line entry system-based: QSAR modelling for MAP kinase-interacting protein kinase (MNK1), SAR QSAR Environ. Res. 26 (2015), pp. 343–361.
   Google Scholar
• K. Bouhedjar, S. Manganelli, G. Gini, A.A. Toropov, A.P. Toropova, S.A. Mokhnache, and D. Messadi, QSAR modeling useful in anti-cancer drug discovery: Prediction of V600EBRAF-dependent P-ERK using Monte Carlo method, J. Med. Chem. Toxicol. 2 (2017), pp. 34–39.
   Google Scholar
• A. Rescifina, G. Floresta, A. Marrazzo, C. Parenti, O. Prezzavento, G. Nastasi, M. Dichiara, and E. Amata, Sigma-2 receptor ligands QSAR model dataset, Data in Brief 13 (2017), pp. 514–535.
   Google Scholar
• L. Simon, A. Imane, K.K. Srinivasan, L. Pathak, and I. Daoud, In silico drug-designing studies on flavanoids as anticolon cancer agents: Pharmacophore mapping, molecular docking, and Monte Carlo method-based QSAR modeling, Interdiscip. Sci. Comput. Life Sci. 9 (2017), pp. 445–458.
   Web of Science ®Google Scholar
• V. Stoičkov, D. Stojanović, I. Tasić, S. Šarić, D. Radenković, P. Babović, D. Sokolović and A.M. Veselinović, QSAR study of 2,4-dihydro-3H-1,2,4-triazol-3-ones derivatives as angiotensin II AT1 receptor antagonists based on the Monte Carlo method, Struct Chem. 29 (2017), pp. 441–449.
   Google Scholar
• S. Bhargava, N. Adhikari, S.A. Amin, K. Das, S. Gayen, and T. Jha, Hydroxyethylamine derivatives as HIV-1 protease inhibitors: A predictive QSAR modelling study based on Monte Carlo optimization, SAR QSAR Environ. Res. 28 (2017), pp. 973–990.
   Google Scholar
• A.A. Toropov, A.P. Toropova, and E. Benfenati, QSAR modelling for mutagenic potency of heteroaromatic amines by optimal SMILES-based descriptors, Chem. Biol. Drug. Des. 77 (2009), pp. 301–312.
   Google Scholar
• E. Benfenati, A.A. Toropov, A.P. Toropova, A. Manganaro, and R.G. Diaza, CORAL software: QSAR for anticancer agents, Chem. Biol. Drug Des. 77 (2011), pp. 471–476.
   Google Scholar
• A. Kumar and S. Chauhan, QSAR differential model for prediction of SIRT1 modulation using Monte Carlo method, Drug Res. 67 (2016), pp. 156–162.
   Google Scholar
• J. Shamsara, Ezqsar: An R package for developing QSAR models directly from structures, Open Med. Chem. J. 11 (2017), pp. 212–221.
   Google Scholar
• P.K. Ojha, I. Mitra, R.N. Das, and K. Roy, Further exploring rm1 metrics for validation of QSPR models, Chemom. Intell. Lab. Syst. 107 (2011), pp. 194–205.
   Web of Science ®Google Scholar
• A. Kumar and S. Chauhan, Use of the Monte Carlo method for OECD principles-guided QSAR modeling of SIRT1 inhibitors, Arch. Pharm. Chem. Life Sci. 350 (2017), pp 1–9.
   Google Scholar
• P.K. Ojha and K. Roy, Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection, Chemom. Intell. Lab. Syst. 109 (2011), pp. 146–161.
   Web of Science ®Google Scholar
• K. Roy, R.N. Das, P. Ambure, and R.B. Aher, Be aware of error measures. Further studies on validation of predictive QSAR models, Chemom. Intell. Lab. Syst. 152 (2016), pp. 18–33.
   Google Scholar
• K. Roy, MLR Plus Validation; software available at http://dtclab.webs.com/software-tools and http://teqip.jdvu.ac.in/QSAR_Tools/.
   Google Scholar
• A. Kumar and S. Chauhan, Monte Carlo method based QSAR modelling of natural lipase inhibitors using hybrid optimal descriptors, SAR QSAR Environ. Res. 28 (2017), pp. 179–197.
   Google Scholar
• A.A. Toropov, A.P. Toropova, F. Como, and E. Benfenati, Quantitative structure–activity relationship models for bee toxicity, Toxicol. Environ. Chem. 99 (2016), pp. 1–12.
   Web of Science ®Google Scholar
• M. Golubović, M. Lazarević, D. Zlatanović, D. Krtinić, V. Stoičkov, B. Mladenović, D.J. Milić, D. Sokolović, and A.M. Veselinović, The anesthetic action of some polyhalogenated ethers −Monte Carlo method based QSAR study, Comput. Biol. Chem. 75 (2018), pp. 32–38.
   Google Scholar
• A. Worachartcheewana, C. Nantasenamata, C.I.N. Ayudhyab and V. Prachayasittikul, QSAR study of H1N1 neuraminidase inhibitors from influenza A virus, Lett. Drug Design Discov. 11 (2014), pp. 420–427.
   Google Scholar
• O. Trott and A.J. Olson, AutoDockVina: Improving the speed and accuracy of docking with a newscoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010), pp. 455–461.
   Google Scholar
• S. Bhargava, T. Patel, R. Gaikwad, U.K. Patiland, and S. Gayen, Identification of structural requirements and prediction of inhibitory activity of natural flavonoids against Zika virus through molecular docking and Monte Carlo based QSAR simulation, Nat. Prod. Res. 15 (2017), pp. 1–7.
   Google Scholar
• Discovery Studio Visualizer, Accelrys Inc, San Diego, CA, 2013.
   Google Scholar